Week in Review: PW Medtech Pays $130 Million for Fellow China Medical Device Company

PW Medtech Group of China paid $130 million to acquire fellow device maker Beijing Tianxinfu Medical Appliance; Walvax Biotech, a vaccine maker that is branching into antibody drugs, raised $72.8 million in a private placement; Cellular Biomedicine Group, a California biotech with a China focus, will acquire Agreen Biotech of China for $22 million; 3SBio in-licensed China rights to a clinical-stage antibody for acute leukemia from DiNonA, a Korean biopharma; Molecular Targeting Technologies of the US will collaborate with Taiwan’s National Health Research Institutes to develop novel cancer drugs; Yabao Pharma partnered with Changzhou Le Sun Pharmaceuticals to co-develop Le Sun's cancer treatment; Solasia Pharma of Tokyo gained global rights for a novel leukemia treatment from Ziopharm Oncology of Boston; Ventana Medical Systems and Quintiles teamed up to offer companion diagnostic testing services in China; and Medtronic officially opened a new manufacturing facility in Chengdu to make hemodialysis machines aimed at second and third tier markets. More details…. Stock Symbols: (SHE: 300142) (NSDQ: CBMG) (SHA: 600351) (NSDQ: ZIOP) (NYSE: MDT) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.